肿瘤个体化治疗的现状和前景

被引：11

作者：

韩晓红 ^{[1
]}

马丽 ^{[2
]}

石远凯 ^{[2
]}

机构：

[1] 北京协和医学院中国医学科学院肿瘤医院肿瘤研究所内科检验科

[2] 北京协和医学院中国医学科学院肿瘤医院肿瘤研究所内科

来源：

中华检验医学杂志 | 2011年 / 04期

关键词：

D O I：

暂无

中图分类号：

R730.5 [肿瘤治疗学];

学科分类号：

100214 [肿瘤学];

摘要：

<正>20世纪70年代以来,人类基因组研究成果斐然,肿瘤基因组学、RNA组学和蛋白质组学等基础研究向临床实践拓展,使传统经验治疗模式逐渐向依据生物标志物的个体化治疗模式转变。越来越多的临床研究证实,通过检测肿瘤患者生物标本中生物标志物的基因突变、基因SNP分型、mRNA基因

引用

共 12 条

[1]

应用FISH和IHC技术检测中国乳腺癌患者HER-2基因状态及蛋白表达的前瞻性多中心研究题录附视频 [J].

韩晓红 ;

石远凯 ;

马丽 ;

吕铮 ;

杨红鹰 ;

姚嘉瑞 ;

李坚 ;

李博 ;

秦燕 .

中华检验医学杂志, 2010, (07)

[2]

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer [J].

Schulz, Christoph ;

Heinemann, Volker ;

Schalhorn, Andreas ;

Moosmann, Nikolas ;

Zwingers, Thomas ;

Boeck, Stefan ;

Giessen, Clemens ;

Stemmler, Hans-Joachim .

WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (40) :5058-5066

[3]

恶性肿瘤个体化治疗靶向药物的临床表现.[J]..中华肿瘤杂志.2010, 10

[4]

Clinical Significance of the 21-Gene Signature (Oncotype DX) in Hormone Receptor-Positive Early Stage Primary Breast Cancer in the Japanese Population [J].

Toi, Masakazu ;

Iwata, Hiroji ;

Yamanaka, Takeharu ;

Masuda, Norikazu ;

Ohno, Shinji ;

Nakamura, Seigo ;

Nakayama, Takahiro ;

Kashiwaba, Masahiro ;

Kamigaki, Shunji ;

Kuroi, Katsumasa .

CANCER, 2010, 116 (13) :3112-3118

[5]

Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: Correlation with clinicopathological parameters [J].

Farzadnia, Mehdi ;

Meibodi, Naser Tayyebi ;

Shandiz, Fatemeh Homayi ;

Mahmoudi, Mahmoud ;

Bahar, Mostafa Mehrabi ;

Memar, Bahram ;

Amoian, Sakineh ;

Maroozi, Farshad ;

Moheghi, Nasrin .

BREAST, 2010, 19 (06) :489-492

[6]

Development of a multiplex MethyLight assay for the detection of multigene methylation in human colorectal cancer [J].

He, Qiong ;

Chen, Hua-Yun ;

Bai, En-Qi ;

Luo, Yan-Xin ;

Fu, Rui-Jia ;

He, Yun-Shao ;

Jiang, Jie ;

Wang, Hua-Qiao .

CANCER GENETICS AND CYTOGENETICS, 2010, 202 (01) :1-10

[7]

Topoisomerase IIα expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer [J].

Schindlbeck, Christian ;

Mayr, D. ;

Olivier, C. ;

Rack, B. ;

Engelstaedter, V. ;

Jueckstock, J. ;

Jenderek, C. ;

Andergassen, U. ;

Jeschke, U. ;

Friese, K. .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (07) :1029-1037

[8]

Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin [J].

Karp, Daniel D. ;

Pollak, Michael N. ;

Cohen, Roger B. ;

Eisenberg, Peter D. ;

Haluska, Paul ;

Yin, Donghua ;

Lipton, Allan ;

Demers, Laurence ;

Leitzel, Kim ;

Hixon, Mary L. ;

Terstappen, Leon W. ;

Garland, Linda ;

Paz-Ares, Luis G. ;

Cardenal, Felipe ;

Langer, Corey J. ;

Gualberto, Antonio .

JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) :1397-1403

[9]

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer [J].

Straver, Marieke E. ;

Glas, Annuska M. ;

Hannemann, Juliane ;

Wesseling, Jelle ;

van de Vijver, Marc J. ;

Rutgers, Emiel J. Th. ;

Peeters, Marie-Jeanne T. F. D. Vrancken ;

van Tinteren, Harm ;

van't Veer, Laura J. ;

Rodenhuis, Sjoerd .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) :551-558

[10]

Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? [J].

Seve, Pascal ;

Dumontet, Charles .

LANCET ONCOLOGY, 2008, 9 (02) :168-175

← 1 2 →